Henry Schein Stock: Is HSIC Underperforming the Health Care Sector?

Company Overview - Henry Schein, Inc. (HSIC) is valued at a market cap of $8.2 billion and is a leading global provider of healthcare products and services, focusing on office-based dental and medical practitioners [1] - The company operates in 33 countries and territories, employing over 25,000 Team Schein members worldwide [1][2] - Henry Schein offers more than 120,000 branded products and private-label offerings, supporting over 1 million customers globally [2] Stock Performance - HSIC currently trades 17.9% below its 52-week high of $82.49 recorded on February 5 [3] - The stock has dropped 6.8% over the past three months, underperforming the Health Care Select Sector SPDR Fund (XLV), which rose by 2% in the same period [3] - Year-to-date, HSIC's stock has declined by 2.1%, while XLV has decreased marginally [4] - Over the past 52 weeks, HSIC shares have slumped 4.2%, significantly underperforming XLV's 11.5% returns [4] - The stock has slipped below its 50-day and 200-day moving averages since the end of July, indicating a downtrend [4] Recent Earnings Report - On August 5, HSIC shares fell 7.4% after the company reported Q2 2025 earnings [5] - The adjusted EPS of $1.10 fell short of Wall Street forecasts, while revenue of $3.2 billion exceeded expectations [5] - The earnings miss was attributed to sluggish demand for U.S. dental products, influenced by high interest rates, inflation, and reduced spending on non-urgent procedures [5] Competitive Landscape - In the healthcare sector, Cardinal Health, Inc. (CAH) has notably outperformed HSIC stock, with CAH shares gaining 30.7% year-to-date and climbing 40.3% over the past 52 weeks [6]